Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALDOCLOR-150 vs TRULANCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Guanylate cyclase-C receptor agonist; increases intracellular c GMP, leading to chloride and water secretion into intestinal lumen and accelerated transit.
Hypertension
Chronic idiopathic constipation (CIC),Irritable bowel syndrome with constipation (IBS-C)
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
3 mg orally once daily.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Terminal elimination half-life is approximately 16 hours, supporting once-daily dosing.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Metabolized by hydrolysis and reduction, not via cytochrome P450; converted to active and inactive metabolites.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Primarily excreted in feces as unchanged drug (approximately 60%) and as metabolites; renal excretion is minimal (<3%).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Approximately 95% bound to plasma proteins, primarily albumin.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Volume of distribution is approximately 2.3 L/kg, indicating extensive tissue distribution.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Absolute bioavailability is approximately 19% after oral administration due to first-pass metabolism.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
No dose adjustment required for mild or moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C); use not recommended.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Safety and efficacy not established in pediatric patients below 18 years of age.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
No specific dose adjustment recommended; however, consider potential increased sensitivity and monitor renal function due to age-related decline.
None.
Not applicable.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Risk of diarrhea, sometimes severe; avoid in patients with suspected or known mechanical gastrointestinal obstruction; caution in patients with severe hepatic impairment.
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Known or suspected mechanical gastrointestinal obstruction; pediatric patients <2 years of age; hypersensitivity to linaclotide or any component of the formulation.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
No significant food interactions; can be taken with or without food.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of harm at clinically relevant exposures. Risk cannot be ruled out; use only if clearly needed.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No data on presence in human milk, effects on breastfed infant, or milk production. Exercise caution; consider developmental and health benefits of breastfeeding alongside maternal need for TRULANCE.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
No dose adjustment recommended based on pharmacokinetic changes; however, clinical data are lacking.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Trulance (plecanatide) is a guanylate cyclase-C agonist indicated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It increases intestinal fluid and transit. Avoid use in patients younger than 6 years due to risk of severe dehydration. Dose is 3 mg once daily; no adjustment for renal or hepatic impairment. Onset may take days to weeks. Titration not needed.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
Take Trulance once daily with or without food.,Swallow tablet whole; do not crush or chew.,Diarrhea is the most common side effect; report severe or persistent diarrhea.,May cause dehydration; drink adequate fluids.,Not recommended in children under 6 years.,Store at room temperature; keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALDOCLOR-150 vs TRULANCE, answered by our medical review team.
ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. TRULANCE is a Guanylate Cyclase-C Agonist that works by Guanylate cyclase-C receptor agonist; increases intracellular c GMP, leading to chloride and water secretion into intestinal lumen and accelerated transit.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALDOCLOR-150 and TRULANCE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. The standard adult dose of TRULANCE is: 3 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALDOCLOR-150 and TRULANCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. TRULANCE is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of harm at clinically relevant exposures. Risk cannot be ruled out; use only if clearly n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.